Skorodumova E. G., Kostenko V. A., Skorodumova E. A., Siverina A. V., Shulenin K. S., Rysev A. V.
St. Petersburg I. I. Dzhanelidze Research Institute of Emergency Medicine, St. Petersburg, Russia

**MODEL OF TWO-YEARS FORECASTING OF THE ANTI-EXISTENT PATIENTS WITH ACUTE DECOMPENSATION OF HEART FAILURE ON THE BACKGROUND OF THE INTERMEDIATE FRACTION OF LEFT VENTRICLE**

**Objective**

Build a prognostic model using clinical, laboratory, and instrumental data to predict mortality in patients with midrange left ventricular ejection fraction (mrLVEF) within two years after hospitalization for acute decompensated heart failure (ADHF).

**Materials and Methods**

The study included 121 patients hospitalized for ADHF with mrLVEF ranging from 40% to 49.9% (91 males and 30 females, mean age 64.6±14.8 years). The independent sample used to validate the statistical model included 71 patients with ADHF and mrLVEF with a mean age of 65.59±12.12 years. Sex distribution of the independent sample was 51 males (70.8% of the independent sample), 20 females (27.8% of the total independent sample). In-hospital mortality of patients included in the study was 4.2%, and long-term mortality was 36.8%. We developed a tool to assess the risk of two-year mortality using classification trees.

**Results**

The root node is the red blood cell distribution width–coefficient of variation (RDW-CV); its diagnostic value in this model was 13.3%. The second-level nodes are glomerular filtration rate (GFR), with a cutoff level of 35 mL/min/1.73 m², and chronic kidney disease (CKD). The third-level nodes are sex, the anterior-posterior dimension of the left atrium, with the cutoff level >47 mm, and low red blood cell count <4.22x10¹²/L. The estimated sensitivity of the model is 71.4%; estimated specificity is 85.7%.

**Conclusion**

This model can be used to assess long-term mortality risk and identify groups of patients with mrLVEF who require closer monitoring.

**Keywords**

Midrange left ventricular ejection fraction; prognostic model; classification tree; acute decompensated heart failure

**For citation**

Skorodumova E. G., Kostenko V. A., Skorodumova E. A., Siverina A. V., Shulenin K. S., Rysev A. V. Model of Two-Years Forecasting of the Anti-Existent Patients with Acute Decompensation of Heart Failure on the Background of the Intermediate Fraction of Left Ventricle. Kardiologiia. 2020;60(1):23–27. [Russian: Скородумова Е. Г., Костенко В. А., Скородумова Е. А., Сиверина А. В., Шуленин К. С., Рысев А. В. Модель двухлетнего прогноза летального исхода у пациентов с острой декомпенсацией сердечной недостаточности с промежуточной фракцией выброса левого желудочка. Кардиология. 2020;60(1):23–27]

**Corresponding author**

Skorodumova Elizaveta. E-mail: lisavetta91@mail.ru

The concept of heart failure with midrange ejection fraction (HFmrEF) of the left ventricle was introduced into Russian clinical practice following the National Congress of Heart Failure in December 2016 [1, 2]. It comprises a left ventricular ejection fraction (LVEF) ranging from 40% to 49.9% [3]. Several studies have shown that patients with HFmrEF may not always have signs and symptoms typical of reduced or preserved left ventricular ejection fraction, and in some cases, symptoms are somewhere in between [4]. A distinctive feature of this category of patients is a clinical picture similar to that of patients with preserved LVEF, combined with a prognosis similar to that of patients with reduced LVEF [5].

Our objective was to build a prognostic model using clinical, laboratory, and instrumental data to predict mortality in patients with HFmrEF within two years of initial hospitalization for acute decompensated heart failure (ADHF).

**Materials and Methods**

The study included 121 patients with LVEF ranging from 40% to 49.9%. Sex distribution of the study sample was 91 males and 30 females. The mean age of patients was 64.6±14.8 years. The independent sample used to validate the statistical model comprised 71 patients with HFmrEF, with a mean age of 65.59±12.12 years. The sex distribution of the independent sample was 51 males (70.8%) and 20 females (27.8%). In-hospital mortality was 4.2%, while long-term (two-year) mortality was 36.8%. All patients were treated under the ADHF treatment protocol, comprising angiotensin-converting enzyme inhibitors, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succinate/bisoprolol, mineralocorticoid-receptor antagonists, and metoprolol succin...
tor antagonists, and loop diuretics. The etiological factors of HFmrEF were coronary artery disease (CAD) in 100% of patients; 46.5% had myocardial infarction and 5.6% had a history of myocarditis. Among the comorbidities, hypertension was the most frequent pathology (92.1%) followed by chronic kidney disease (CKD) (57.1%), diabetes mellitus (DM) (42.3%), and chronic obstructive pulmonary disease (COPD) (28.6%).

Diagnosis of ADHF was based on the typical clinical picture (at least two of the following signs: shortness of breath in New York Heart Association (NYHA) functional class (FC) III–IV, clinical or radiographic pulmonary congestion, peripheral edema, increased jugular pressure, liver enlargement, ascites). We developed a tool to assess the risk of two-year mortality with mathematical modeling approach using classification trees. We created a prognostic model of two-year mortality in patients after the first-time hospitalization using hazard ratio (HR), the chi-squared test, the standardized Pearson correlation coefficient, and the Cramer-von Mises test. We also used a multivariate analysis method with decision trees.

Results

All admitted patients had high FC CHF according to the assessment of reported history of walking distance or a number of flights of stairs climbed.

The theoretical analysis included the comprehensive assessment of death risk factors for two years from first hospitalization. Parameters not meeting the criteria of reliability and validity were eliminated. The final model was based on the parameters shown in Table 1.

Interestingly, GFR was highly correlated (0.965) on the Chaddock scale, as was the anterior-posterior dimension of the left atrium (LA) (0.894) and red blood cell count (RBC) (0.858); the red blood cell distribution width – coefficient of variation (RDW-CV) (0.562) and sex (0.618) showed medium correlation, and history of CKD (0.460) had moderate correlation. Results were evaluated by the Cramer-von Mises test, with similar results (shown in Table 1). Present CKD had moderate correlation (0.344). In the chi-squared test, all parameters of the statistical model were significant: CKD p<0.05, LA dimension p<0.05, and all other parameters p<0.01. Analysis of hazard ratios showed that glomerular filtration rate (GFR) 40–60 mL/min/1.73 m² increased the mortality risk 14.5-fold, with a confidence interval (CI) of 5.6–37.3, and the history of CKD doubled the mortality risk [1.2–3.4]. The integrated prognostic model for mortality is shown in Figure 1.

As Figure 1 shows, the root node is the red blood cell distribution width-variation coefficient (RDW-CV); its diagnostic value in this model was 13.3%. Second-level nodes are GFR with a cutoff level of 40 mL/min/1.73 m² and a history of CKD. Third-level nodes are sex, the anterior-posterior dimension of LA (cutoff level >47 mm), and RBC count (cutoff level 4.22 x 1012/L).

As seen in this model, male patients with RDW-CV <13.3% and GFR >30 mL/min/1.73 m² are at lower risk of death than female patients with the same parameters (HR for RDW-CV in the subgroups of deceased and surviving patients is 2.32 [1.7; 3.2], and HR for GFR is 14.5 [5.6; 37.3]).

At the same time, the mortality risk increased manyfold to reach 100% in patients with GFR <30 mL/min/1.73 m² and the same level of RDW-CV. When patients with a history of CKD (HR 2 [1.2; 3.4]) had RDW-CV >13.3%, mortality risk depended on the anterior-posterior dimension of LA (HR not applicable). The larger dimensions were associated with a mortality risk of 84.2%; at the same time, the mortality risk was not high in patients with LA <47 mm. The RBC cutoff level of 4.22x1012/L is a significant factor in patients with RDW-CV >13.3% and without a history of CKD. The mortality risk in patients with RBC count <4.22x1012/L was 87.5%, and decreased to 11.1% in patients whose RBC exceeded this value.

Table 1. Validation of model parameters and correlation with long-term mortality (24 months)

| Parameter | HR | CI          | Chi-squared test | Cramer-von Mises test | Standardized Pearson's coefficient |
|-----------|----|-------------|------------------|-----------------------|-----------------------------------|
| RDW-CV    | 2.32 | [1.7; 3.2] | 24.4**          | 0.433                 | 0.562                             |
| GFR       | 14.5 | [5.6; 37.3] | 101.0**         | 0.933                 | 0.965                             |
| CKD       | 2    | [1.2; 3.4] | 7.6*            | 0.344                 | 0.460                             |
| Sex       | N/A  | N/A         | 36.1**          | 0.486                 | 0.618                             |
| LA        | N/A  | N/A         | 13.3*           | 0.816                 | 0.894                             |
| RBC       | 9    | [2; 34]     | 24.4**          | 0.763                 | 0.858                             |

*p<0.05; **p<0.01. HR, hazard ratio; CI, confidence interval; RDW-CV, red blood cell distribution width-variation coefficient; GFR, glomerular filtration rate; CKD, chronic kidney disease; LA, anterior-posterior dimension of the left atrium; N/A, not applicable.
Example 1. Male patients with ADHF and midrange LVEF (mrLVEF), GFR 85 mL/min/1.73 m², RDW-CV 16.4%, no history of CKD, anterior-posterior dimension of LA 44 mm, and RBC count 4,62x10¹²/L. According to the model, RDW-CV is diagnostically significant: in this case, its value exceeds the cutoff level of 13.3% (right side of the model). Since the patient has no history of CKD, the next relevant factor is RBC count, which also exceeds the diagnostic cutoff value of 4.22x10¹²/L. Thus, the estimated mortality risk according to the classification tree is 11.1%.

Example 2. Female patients with ADHF and mrLVEF, GFR 51 mL/min/1.73 m², RDW-CV 12.1%, no history of CKD, anterior-posterior dimension of LA 45 mm, and RBC count 4.53x10¹²/L.

According to the model, RDW-CV is diagnostically significant: in this case, its value is less than 13.3% (left side of the model). Since this patient has a history of GFR >35 mL/min/1.73 m², the next relevant factor is sex. The estimated risk of mortality according to the classification tree is 33.3%.

This multifactorial model was verified using ROC analysis (Figure 2).

The estimated sensitivity of the model is 71.4%, specificity – 85.7%. The area under the curve is 0.849, which corresponds to “very good” on the expert scale for AUC values.
The estimated sensitivity of the model is 88.1%, with an estimated specificity of 91.8%. The area under the curve is 0.965, which corresponds to “very good” on the expert scale for AUC values. The validity of the model is 89.2%.

Discussion

The prognosis of adverse outcomes, mortality in particular, in patients with CHF and midrange LVEF must acknowledge that additional risk factors include conditions resulting from structural and functional changes to other than the heart [4–9].

There is very little information in the literature on using mathematical modeling for prognosis in patients with CHF and midrange LVEF. The available data show that LVEF and CHF FC have a low prognostic value [8–13]. In the Seattle Heart Failure Model, among the most significant in the univariate analysis are the following parameters: age, male sex, present CAD, low body mass index, LVEF, blood pressure, blood sodium levels, cholesterol, hemoglobin, and CHF of NYHA FC III–IV, leukocytosis, high blood levels of creatinine and uric acid, administration of allopurinol and co-administration of thiazide and loop diuretics; all increased the risk of mortality [14]. A comparison of the effectiveness of the Seattle model versus SurvVivAl (NEVA-75) in the Russian population found that the Seattle model overestimates the survival rate by 4% to 19% [15].

Our model, based on analysis of the Russian population, shows the prognostic algorithm for mortality within two years after initial hospitalization.

Conclusion

1. Based on analysis of the Russian population, this mathematical model allows determination of mortality risk in patients with CHF and midLVEF within two years after first hospitalization.

2. The most significant factors for high mortality risk are red blood cell distribution width-variation coefficient, glomerular filtration rate, chronic kidney disease, anterior-posterior dimension of the left atrium, and red blood cell count.

No conflict of interest is reported.

The article was received on 30/01/19

REFERENCES

1. Lam CSP, Solomon SD. The middle child in heart failure: heart failure with mid-range ejection fraction (40-50%). European Journal of Heart Failure. 2014;16(10):1049–55. DOI: 10.1002/ejhf.159

2. Kostenko V.A., Sitnikova M.Yu., Skorodumova E.A., Fedorov A.N., Skorodumova E.G. New Scale for Assessment of Prognosis of Survival for Two Years After Hospitalization Because of Acute Decompensation of Heart Failure. Kardiologiia. 2017;57(6):33–9. [Russian: Kostenko V.A., Sitnikova M.Yu., Skorodumova E.A., Fedorov A.N., Skorodumova E.G. Новая шкала оценки двухлетнего прогноза выживаемости для пациентов, госпитализированных в многопрофильный стационар по поводу острой декомпенсированной сердечной недостаточности. Кардиология. 2017;57(6):33–9]  

3. Skorodumova E.G., Kostenko V.A., Skorodumova E.A., Rysev A.V. Problems and specificity of diagnostics of acute heart failure in patients with intermediate ejection fraction at the hospital stage. Emergency Medical Care. 2018;19(1):16–9. [Russian: Skorodumova E.G., Kostenko V.A., Skorodumova E.A., Rysev A.V. Проблемы и специфичность диагностики острой сердечной недостаточности у пациентов с пограничной функцией левого желудочка на догоспитальном этапе. Скорая медицинская помощь. 2018;19(1):16–9]  

4. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal. 2016;37(27):2129–200. DOI: 10.1093/eurheartj/ehw128

5. Komajda M, Lam CSP. Heart failure with preserved ejection fraction: a clinical dilemma. European Heart Journal. 2014;35(16):1022–32. DOI: 10.1093/eurheartj/ehu067

6. Kociol RD, Hammill BG, Fonarow GC, Klaszka W, Mills RM, Hernandez AF et al. Generalizability and longitudinal outcomes of a national heart failure clinical registry: Comparison of Acute Decompensated Heart Failure National Registry (ADHERE) and non-ADHERE Medicare beneficiaries. American Heart Journal. 2010;160(5):885–92. DOI: 10.1016/j.ahj.2010.07.020

7. Hülsmann M, Berger R, Mörtl D, Pacher R. Influence of age and in-patient care on prescription rate and long-term outcome in chronic heart failure: a data-based substudy of the EuroHeart Failure Survey. European Journal of Heart Failure. 2005;7(4):657–61. DOI: 10.1016/j.ejhf.2004.11.011

8. Martinsson A, Oest P, Wiborg M-B, Reitan Ö, Smith JG. Longitudinal evaluation of ventricular ejection fraction and NT-proBNP across heart failure subgroups. Scandinavian Cardiovascular Journal. 2018;52(4):205–10. DOI: 10.1080/14017431.2018.1461920

9. Karabag Y, Çınar T, Çağdaş M, Rencizoğulları İ, Tanık VO. In-hospital and long-term prognoses of patients with a mid-range ejection frac-
10. Lauritsen J, Gustafsson F, Abdulla J. Characteristics and long-term prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure. 2018;5(4):685–94. DOI: 10.1002/ehf2.12283

11. Mavrea A, Korpos-Gyalai I, Citi I, Ancusa O, Bordejevic A, Tomescu MC. Long-term prognosis and modes of death in heart failure patients with reduced versus preserved left ventricular systolic function. European Scientific Journal. 2013;3:246–53. [Av. at: https://eujournal.org/index.php/esj/article/view/2431/2304]

12. Zafrir B, Lund LH, Laroche C, Ruschitzka F, Crespo-Leiro MG, Coats AJS et al. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry. European Heart Journal. 2018;39(48):4277–84. DOI: 10.1093/eurheartj/ehy626

13. Leng S, Tan R-S, Zhao X, Allen JC, Koh AS, Zhong L. Validation of a rapid semi-automated method to assess left atrial longitudinal phasic strains on cine cardiovascular magnetic resonance imaging. Journal of Cardiovascular Magnetic Resonance. 2018;20(1):71–6. DOI: 10.1186/s12968-018-0496-1

14. Mozaffarian D, Anker SD, Anand I, Linker DT, Sullivan MD, Cleland JGF et al. Prediction of mode of death in heart failure: the Seattle Heart Failure Model. Circulation. 2007;116(4):392–8. DOI: 10.1161/CIRCULATIONAHA.106.687103

15. Shlyakhto E.V., Sitnikova M.Yu., Lelyavina T.A., Ivanov S.G., Трукшина М. А., Fedotov П. А. et al. Current algorithms for evaluation of prognosis in patients with CHF. Comparative characteristics of BNP – age-related model of survival (NEVA-75) and Seattle Heart Failure Model in patients aged 75–85 years. Russian Heart Failure Journal. 2009;10(1):4–7. [Russian: Шляхто Е.В., Ситникова М.Ю., Лелявина Т.А., Иванов С.Г., Трукшина М. А., Федотов П. А. и др. Современные алгоритмы оценки прогноза у больных ХСН. Сравнительная характеристика МНП-возрастной модели выживаемости (НЕВА-75) и Сиэттлской модели сердечной недостаточности (Seattle Heart Failure Model) у больных 75-85 лет. Журнал Сердечная Недостаточность. 2009;10(1):4-7]